

Date: 31-01-2019

To
Mr. BhushanMokashi
Manager
Bombay Stock Exchange Limited,
PhirozeJeeJeebhoy Towers,
Dalai Street, MUMBAI – 400 001.

Sir,

Sub: Outcome of the Board Meeting – Reg. Ref: Our Company code no: 532041.

Hyderabac

The following is the Outcome of the Board Meeting of the Company held on 31st January, 2019 at 02.00 P.M. at the registered office of the Company:

1 The Board has approved the un-audited financial results of the company for the quarter ended on 31st December, 2018.

We are herewith enclosing un-audited financial results of the company & Limited Review Report certified by the auditor for the quarter ended 31.12.2018, as per Clause 33 (3) of SEBI (LODR) Regulations, 2015.

This is for your information and record.

Thanking you

Yours faithfully,

For Hindustan Bio Sciences Limited

J V R Mohan Raju Managing Director

> Plot No. 31, Sagar Society, Road No. 2, Banjara Hills, Hyderabad - 500 034. INDIA. Ph.: 040-23555161, 23555181, Fax: 040-40205171

Email: pharma.hindustanbio@gmail.com CIN: L26942TG1991PLC013564

HINDUSTAN BIO SCIENCES LIMITED

Plot No.31, Sagar Society, Road No.2, Banjara Hills, Hyderabad 500 034 Phone No. 23555161,Fax 40205171

STATEMENT OF UN AUDITED RESULTS FOR THE QUARTERININE MONTHS ENDED 31st DECEMBER, 2018

19							(Rs. In Lakhs
SI.		Quarter ended			Nine months ended		Year Ended
No.		31.12.2018	30.09.2018	31.12.2017	31.12.2018	31,12,2017	31.03.2018
-	- Marine	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(unaudited)	(Audited)
1	Income from Operations						
	(a) Revenue from operations	107.03	147.39	36.93	313.29	44.29	103,11
	(b) Other Income			-	13-20-03/03	1/200	9.22
	Total Revenue (1)	107.03	147.39	36,93	313.29	44.29	112.33
2	Expenses		1 9 7 1 9 5 5 5	35500	0.000000	(883876)	1030000
	(a) cost of material consumed			2			
	(b) Purchases of Stock -in-trade	73.95	160.09	8.32	269,21	24.46	64.69
	(c) Changes in Inventories of finished goods, Stock -						-
	in-Trade and Work-in-Progress	6.86	(24.10)	11.84	(9.31)	2.7	(7,93
	(d) Employee Benefit Expenses	6.16	5.07	5.56	16.15	16.60	22.03
	(e) Finance Costs	0.40	0.13	0.18	0.75	0.30	0.38
	(f) Selling Expenses	0.75	0.14	0.52	1.22	0.54	1.25
	(g) Depreciation and amortisation Expenses	0.25	0.27	0.24	0.78	0.69	0.96
	(h) Debit Balances Written off				0.70	0.03	10.000
- 0	(h) Other Expenses	11.15	3.46	10.98	24.83	20.18	234.96
	Total Expenses(2)	99.52	.145.06	37.64	303.63	62.77	23.11
3	Profit/(Loss) before Exceptional& Extraordinary items and tax (1 -2)	7.51	2.33	(0.71)	9.66	(18.48)	339.45
4	Exceptional items		2.50	(0.77)	3,00	10758577	(227.12
5	Profit/(Loss) before tax(3 -4)	7.51	2.33	(0.71)	0.00	***	1022
6	Tax Expenses	7.01	4,00	40.71)	9.66	(18.48)	(227.12)
	(a) Current Tax	2.1	1237	133			
	(b) Deferred Tax			· •			
7	Profit /(Loss) for the period from continuing operations(5-6)	7.51	2.22		200	Sept.	(0.40)
8	Profit /(Loss) from discontinued operations	1.01	2.33	(0.71)	9.66	(18.48)	(227.52)
9	Tax Expense of discontinued operations	1 1	- 3				1-6
10	Profit /Loss from Discontinued operations after tax(8-9)	1 1	- 1	75	38.	* 1	
11	Profit/(Loss) for the period(7+10)	7.51	2.22	10.74		25.36	-
	Other Comprehensive Income	7.31	2.33	(0.71)	9.66	(18.48)	(227.52)
	A (1) Items that will not be reclassified to profit or loss	1 231		- 1	- 1	- 1	
- 1	(2) Income tax relating to items that will not be re-				- 30		(ia
- 1	classified to profit or loss	1 1		1		- 1	
	B (1) Items that will be reclassified to profit or loss	1 23		1.00	*	8	5÷
	(2) Income tax relating to items that will be reclassified			-	-		9.7
- 1	to profit or loss						
13	Total Comprehensive Income for the period (11+12)	**	or Pass	-			1 -
	Comprehensive Income for the period (11+12)	7.51	2.33	(0.71)	9.66	(18.48)	(227.52)
14	(comprising Profit (Loss) and other comprehensive Income for the period Paid up Equity Capital(Face value of Rs. 10/- each)	1200000	2.84	- 0	- 1	200 20	10000000
15	Reserves excluding Revaluation Reserves as per balance sheet of	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08	1,025.08
100	previous accounting year	1 1		- 1			200000000000000000000000000000000000000
			- 1	- 1	- 1	- 1	(819.72)
	Earnings per equity share for continuing operations (A) Basic		- 1	- 1	- 1		2000000000
	B) Diluted	0.07	0.02	(0.01)	0.09	(0.18)	(2.22)
	Earnings per equity share for discontinuing operations	0.07	0.02	(0.01)	0.09	(0.18)	(2.22)
	A) Basic						
	B) Diluted		-	0.20			181
	amings per equity share(for discontinuing & continuing operations		- 1				9
- 14	A) Basic	0.07	0.02	(0.04)	0.00	77,2337	1000000
tes:	B) Diluted	0.07	0.02	(0.01)	0.09	(0.18)	(2.22)

1 The Un Audited Financial Results were taken on record by the Board of Directors in their meeting held on 31.01.2019

2 Previous Year figures have been regrouped wherever necessary

fgr-Hindustan Bio Sciences Limited

J.V.R.Mohan Raju Managing Director

Place Hyderabad Date 31.01.2019



3-6-237, Unit # 606, Lingapur La Builde Complex, Himayatnagar, Hyderabad - 500 029.

Ph: 23264144/45, 23223787 E-mail: crcoca@gmail.com

Limited Review Report

Review Report to The Board of Directors Hindustan Bio Sciences Ltd.

We have reviewed the accompanying statement of unaudited financial results of M/s. Hindustan Bio Sciences Limited ('the Company') for the quarter ended December 31, 2018 ('the Statement') attached herewith, being submitted by the Company pursuant to the requirements of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 date July 05, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on the statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditors of the Entity, issued by the institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We do no express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognized accounting practices and policies, has not disclosed the information required to be disclosed in terms of Regulations 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 date July 05, 2016 including the manner in which it is to be disclosed, or that it contains any material misstatement.

HANDA

FRM: 002884S

HYDERASAD

Place: Hyderabad Date:28.01.2019 For C.RAMACHANDRAM & Co.,

Chartered Accountants Firm Reg No. 002864S

C.RAMACHANDRAM

Partner M.No:025834